Lung Cancer News
At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.
Previous studies have demonstrated that crizotinib — a tyrosine kinase inhibitor (TKI) of ALK, MET, and ROS1 kinases — has markedly increased antitumor activity among patients with ROS1-positive NSCLC.
Few long-term data of the drug's safety and efficacy in patients with NSCLC were previously available.
Researchers are evaluating whether early integrated palliative care yields superior quality of life outcomes to stepped palliative care.
Cancer-associated weight loss is linked to worse survival outcomes among patients with cancer.
The safety profile of each agent was consistent with those previously reported.
Researchers evaluated whether different complex mutations lead to different clinical outcomes among patients treated with EGFR-TKIs.
Previous studies demonstrated that fruquintinib may have clinical value for patients who fail at least 2 prior lines of therapy.
AZD1775 is an inhibitor of the Wee1 kinase, which is linked to chemotherapy resistance.
Researchers are evaluating the efficacy of tremelimumab plus durvalumab alone or with radiation therapy among patients with SCLC.
Researchers are comparing the effectiveness of pembrolizumab with that of topotecan among patients with SCLC.
Non-cigarette tobacco use has increased by over 100% in the last 2 decades.
The FDA based its approval on positive findings from the phase 3 PACIFIC study.
Researchers are evaluating whether avelumab, a PD-L1 inhibitor, is safe and effective in combination with chemotherapy for treating patients with NSCLC or urothelial cancer.
Researchers are evaluating whether adding a dendritic cell-based p53 vaccine to combination checkpoint inhibition will improve outcomes among patients with recurrent SCLC.
Researchers retrospectively analyzed the outcomes of 78 patients with stage IV lung SCC who were treated with gemcitabine plus cisplatin as first-line therapy.
Living in a lower-education area and being African American were associated with not receiving any cancer-directed care.
PSPT significantly reduced radiation exposure to the heart, but no differences were observed between PSPT and IMRT for the lung or esophagus.
FDA Accepts Supplemental New Drug Application for Osimertinib as First-line Treatment in EGFR-mutant NSCLC
Data from FLAURA may position osimertinib as the first-line standard of care for patients with EGFR-mutant NSCLC.
Researchers are evaluating whether patients with metastatic NSCLC will benefit from stereotactic body radiation and a virally mediated gene therapy prior to nivolumab.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Rectal Cancer: Adjuvant Chemotherapy May Improve OS After pCR
- Breast Cancer: Determining the Best Diet for Disease Prevention
- Hormone Therapy for Breast Cancer May Cause Diabetes
- Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers
- Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma